Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer’s disease

Overview of attention for article published in Alzheimer's Research & Therapy, December 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#20 of 1,320)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

So far, Altmetric has seen 32 news stories from 32 outlets.

STOCKHOLM, March 31, 2023 /PRNewswire BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today the…

Please enter a search term. Please enter a search term. News provided by Mar 31, 2023, 2:14 AM ET STOCKHOLM, March 31, 2023 /PRNe…

TOKYO and CAMBRIDGE, Mass., March 30, 2023 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and…

TOKYO and CAMBRIDGE, Mass., March 30, 2023 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 28 additional news stories.